
TY  - JOUR
AU  - Lin,             M.P.
AU  - Marti, G.P.
AU  - Dieb, R.
AU  - Wang, J.
AU  - Ferguson, M.
AU  - Qaiser, R.
AU  - Bonde, P.
AU  - Duncan, M.D.
AU  - Harmon, J.W.
TI  - 063 Electroporation-Facilitated Gene Therapy for Wound Healing
JO  - Wound Repair and Regeneration
VL  - 13
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1067-1927.2005.130215bk.x
DO  - doi:10.1111/j.1067-1927.2005.130215bk.x
SP  - A4
EP  - A27
PY  - 2005
AB  - Introduction:? Using peptide growth factors to improve upon natural wound healing provides promise, but topical application of growth factors has found limited clinical success. Gene therapy has been limited by low transfection efficiency. We are investigating the use of electroporation (EP)in vivo to enhance transfection efficiency and improve wound healing with DNA expression vectors for growth factors. Methods:? To assess plasmid transfection and wound healing, gWIZ luciferase vector and PCDNA3.1/KGF expression vector were used, respectively. Cutaneous wounds were produced via 8?mm-punch biopsy in Sprague Dawley rats. Healing was impaired by cecal ligation induced sepsis. We used NIH image analysis software and histologic assessment to assess wound closure. Results:? Plasmid Transfection: EP effectively increased expression of gWIZ luciferase vector 53-fold compared to vector without EP (p?<?0.001). We demonstrated that transfection was localized to skin when transfected skin was reflected to reveal underlying muscle. We found that EP-assisted transfection lasted for 30 days, which is appropriate for treatment of wound healing. Wound Healing:? Using PCDNA3.1/KGF expression vector and EP wounds were 60% smaller on day 12 versus vector without EP (p?<?0.009). We assessed quality of healing with a histologic scoring system grading quality of epithelial coverage, organization of scar and resolution of inflammation. KGF vector?+?EP score of 3.0 +/? 0.3 was better than that of 1.8 +/? 0.3 for treatment with vector alone (p?<?0.05). Conclusions:? These results demonstrate the capacity of electroporation-facilitated transfection with DNA plasmid expression vector for growth factor to improve wound healing. Acknowledgments:? Funding from USAMRMC PRMRP DAMDI7-03-1-0029 and Maryland State Firefighters Fund
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of Gastroenterology and Hepatology
VL  - 19
IS  - s5
SN  - 0815-9319
UR  - https://doi.org/10.1111/j.1440-1746.2004.03623.x
DO  - doi:10.1111/j.1440-1746.2004.03623.x
SP  - A324
EP  - A500
PY  - 2004
ER  - 

TY  - JOUR
TI  - 44th Congress of the International Society of Paediatric Oncology (SIOP) 2012, London, United Kingdom, 5th–8th October, 2012 SIOP abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 59
IS  - 6
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.24295
DO  - doi:10.1002/pbc.24295
SP  - 965
EP  - 1152
PY  - 2012
ER  - 

TY  - JOUR
AU  - Dworkin, Robert H.
AU  - Perkins, Frederick M.
AU  - Nagasako, Elna M.
TI  - Neurology (55)
JO  - Pain Practice
JA  - Pain Practice
VL  - 1
IS  - 1
SN  - 1530-7085
UR  - https://doi.org/10.1111/j.1533-2500.2001.1011-55.x
DO  - doi:10.1111/j.1533-2500.2001.1011-55.x
SP  - 104
EP  - 104
PY  - 2001
AB  - Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. (University of Rochester School of Medicine and Dentistry, Rochester, NY) Clin J Pain 2000;16:S90?100. This review discussed the results of recent studies that have identified risk factors for the development of postherpetic neuralgia (PHN) and have implicated several peripheral and central mechanisms in its pathophysiology. These risk factors and mechanisms of PHN provide a basis for hypothesizing that combining antiviral therapy with analgesic treatment beginning as soon as possible after the onset of herpes zoster would reduce the risk of PHN beyond that achieved by antiviral therapy alone. Conclude this treatment approach would be expected to reduce the risk of PHN in herpes zoster patients by attenuating acute pain and thereby preventing the initiation of central mechanisms of chronic pain.
ER  - 

TY  - JOUR
TI  - Monday, 6 July 1998
JO  - British Journal of Haematology
VL  - 102
IS  - 1
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.1998.tb08995.x
DO  - doi:10.1111/j.1365-2141.1998.tb08995.x
SP  - 2
EP  - 139
PY  - 1998
ER  - 

TY  - JOUR
TI  - Scientific Exhibits
JO  - Journal of Medical Imaging and Radiation Oncology
JA  - Journal of Medical Imaging and Radiation Oncology
VL  - 58
IS  - S1
SN  - 1754-9477
UR  - https://doi.org/10.1111/1754-9485.12223
DO  - doi:10.1111/1754-9485.12223
SP  - 184
EP  - 343
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Alcoholism: Clinical and Experimental Research
VL  - 36
IS  - s2
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2012.01917.x
DO  - doi:10.1111/j.1530-0277.2012.01917.x
SP  - 1A
EP  - 152A
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 25
IS  - S1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.13635
DO  - doi:10.1111/ene.13635
SP  - 1
EP  - 65
PY  - 2018
ER  - 

TY  - JOUR
TI  - ASBMR 30th Annual Meeting M001–M507
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 23
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650231306
DO  - doi:10.1002/jbmr.5650231306
SP  - S374
EP  - S505
PY  - 2008
ER  - 

TY  - JOUR
TI  - Scientific Exhibits
JO  - Journal of Medical Radiation Sciences
JA  - J Med Radiat Sci
VL  - 61
IS  - S1
SN  - 2051-3895
UR  - https://doi.org/10.1002/jmrs.74
DO  - doi:10.1002/jmrs.74
SP  - 184
EP  - 343
PY  - 2014
ER  - 

TY  - JOUR
TI  - 45th Annual Meeting of the Child Neurology Society
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 80
IS  - s20
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.24756
DO  - doi:10.1002/ana.24756
SP  - S267
EP  - S432
PY  - 2016
ER  - 

TY  - JOUR
TI  - American Society of Transplant Surgeons: 13th Annual State of the Art Winter Symposium
JO  - American Journal of Transplantation
VL  - 13
IS  - s2
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.12085
DO  - doi:10.1111/ajt.12085
SP  - 53
EP  - 99
PY  - 2013
ER  - 

AU  - Lunn, Michael
AU  - Hanna, Michael
AU  - Howard, Robin
AU  - Parton, Matthew
AU  - Reilly, Mary
C7  - pp. 337-410
TI  - Nerve and Muscle Disease
SN  - 9781405134439
UR  - https://doi.org/10.1002/9781444311709.ch9
DO  - doi:10.1002/9781444311709.ch9
SP  - 337-410
KW  - nerve and muscle disease
KW  - inherited neuropathies
KW  - classification of inherited neuropathies
KW  - chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
KW  - focal and compressive neuropathies
KW  - hereditary neuropathy
PY  - 2013
AB  - Summary This chapter contains sections titled: Peripheral nerve disorders Diseases of the peripheral nerve Inherited neuropathies Acquired neuropathies Focal and compressive neuropathies Anterior horn cell diseases Spinal muscular atrophy Disorders of the neuromuscular junction Muscle diseases References
ER  - 

TY  - JOUR
AU  - Van Hilten, J.J.
AU  - Van de Beek, W.J.T.
AU  - Roep, B.O.
TI  - Neurology (51)
JO  - Pain Practice
JA  - Pain Practice
VL  - 1
IS  - 1
SN  - 9781405134439
UR  - https://doi.org/10.1111/j.1533-2500.2001.1011-51.x
DO  - doi:10.1111/j.1533-2500.2001.1011-51.x
SP  - 103
EP  - 103
PY  - 2001
AB  - Regional pain syndrome: a distinct clinical entity associated with HLA-DR13. (Leiden University Medical center. Leiden, The Netherlands) Ann Neurol 2000;48:113?116. This report discussed 26 patients with a distinct phenotype of complex regional pain syndrome that progressed toward a multifocal or generalized tonic dystonia. The dystonia initiated distally, involved mainly flexor muscles, and was associated with sensory and autonomic symptoms. Dryness of the eyes or mouth and bladder and bowel disturbances were frequently reported. There was no increase in the familial prevalence of autoimmune-mediated disease. Compared with controls, a significant elevation of HLA-DR13 was found in the patients. Thus, HLA-DR13 may be a factor indicating susceptibility to this distinct phenotype of complex regional pain syndrome.
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 9781405134439
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00025.x
DO  - doi:10.1111/j.1538-7836.2007.tb00025.x
SP  - O-T-001
EP  - O-T-096
PY  - 2007
ER  - 

TY  - JOUR
AU  - Shaw, Kirsty J.
AU  - Birch, Christopher
AU  - Hughes, Elizabeth M.
AU  - Jakes, Adam D.
AU  - Greenman, John
AU  - Haswell, Stephen J.
TI  - Microsystems for personalized biomolecular diagnostics
JO  - Engineering in Life Sciences
JA  - Eng. Life Sci.
VL  - 11
IS  - 2
SN  - 9781405134439
UR  - https://doi.org/10.1002/elsc.201000175
DO  - doi:10.1002/elsc.201000175
SP  - 121
EP  - 132
KW  - Diagnostics
KW  - Healthcare
KW  - Integration
KW  - Microfluidics
KW  - Personalized medicine
PY  - 2011
AB  - Abstract The development of microfluidic methodology that can be used in conjunction with drug screening and biomolecular diagnostics offers a route to evidence-based personalized medical care. Ideally, all personal diagnostics are best carried out in a rapid and frequent manner and a microfluidic interface can provide appropriate methodology. The ability to perform genetic analysis or biomarker detection at point-of-care would allow the clinician to decide on the most informed course of treatment. Microfluidic systems for biomolecular analysis at all levels, from genes to whole tissue biopsies, have been proposed. Much of the work presented here is at an early stage of development but will consider the range of design considerations together with the plethora of potential applications of integrated microfluidic technology.
ER  - 

TY  - JOUR
TI  - Abstracts accepted for publication only
JO  - Clinical Microbiology and Infection
VL  - 18
IS  - s3
SN  - 9781405134439
UR  - https://doi.org/10.1111/j.1469-0691.2012.03803.x
DO  - doi:10.1111/j.1469-0691.2012.03803.x
SP  - 716
EP  - 844
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts from the American Academy of Pediatrics Section on Cardiology and Cardiac Surgery (SOCCS)
JO  - Congenital Heart Disease
JA  - Congenital Heart Disease
VL  - 11
IS  - 5
SN  - 9781405134439
UR  - https://doi.org/10.1111/chd.12421
DO  - doi:10.1111/chd.12421
SP  - 468
EP  - 530
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol.
VL  - 52
IS  - S47
SN  - 9781405134439
UR  - https://doi.org/10.1002/ppul.23840
DO  - doi:10.1002/ppul.23840
SP  - S214
EP  - S516
PY  - 2017
ER  - 

TY  - JOUR
TI  - SIOP 2016 Scientific Programme+Index
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 63
IS  - S3
SN  - 9781405134439
UR  - https://doi.org/10.1002/pbc.26233
DO  - doi:10.1002/pbc.26233
SP  - S5
EP  - S321
PY  - 2016
ER  - 
